IL-6-elafin genetically modified macrophages as a lung immunotherapeutic strategy against Pseudomonas aeruginosa...

Area of Science:

• Immunology
• Cell Therapy
• Pulmonary Medicine

Background:

• Pseudomonas aeruginosa (P.a) infections pose a significant threat, particularly in ventilator-associated pneumonia and chronic lung diseases.
• Multidrug resistance in P.a necessitates the development of novel therapeutic strategies.
• Macrophages are key immune cells involved in lung defense and repair.

Purpose of the Study:

• To evaluate the therapeutic potential of gene-modified syngeneic macrophages in a mouse model of acute P.a lung infection.
• To investigate the protective mechanisms conferred by elafin and IL-6 modified macrophages.
• To assess the impact of cell therapy on lung inflammation and tissue repair.

Main Methods:

• Gene modification of alveolar macrophages (AMs) and bone marrow-derived macrophages (BMDMs) with elafin and adenovirus IL-6 (Ad-IL-6).
• In vitro characterization of modified cells.
• Oropharyngeal instillation of modified cells into mice followed by P.a infection.
• Assessment of survival rates and analysis of inflammatory responses.

Main Results:

• A single administration of genetically modified syngeneic AMs or BMDMs significantly protected mice against P.a-induced acute lung infection.
• Elafin-modified macrophages exhibited a specific molecular signature (IL-6-IL-10-IL-4R-IL-22) associated with antimicrobial activity.
• Combined modification with elafin and IL-6 enhanced epithelial cell proliferation and promoted tissue repair in the alveolar unit.

Conclusions:

• Direct pulmonary transplantation of gene-modified macrophages represents an innovative cell therapy approach for acute bacterial lung infections.
• This strategy leverages synergistic effects of elafin and IL-6 to bolster host defense and facilitate lung tissue regeneration.
• The findings suggest a promising new avenue for combating challenging multidrug-resistant P.a infections.